| Description | YIAD-0205, an orally administered inhibitor of Aβ(1-42) aggregation, has exhibited in vivo efficacy in a 5XFAD transgenic mouse model that harbors five familial AD mutations [1]. |
| In vitro | YIAD-0205在10 μM及100 μM的浓度下能够抑制Aβ（1-42）的聚集[1]。 |
| In vivo | YIAD-0205（50 mg/kg；口服；每周两次，连续四周）在6.0个月龄的5XFAD小鼠模型中，显著减少Aβ斑块和Aβ寡聚物的负荷[1]。 |
| molecular weight | 565.69 |
| Molecular formula | C26H16Br2ClN3 |
| CAS | 2446054-34-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |